$17.27
+12%Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Thin margins leave little room for error. Cost management and pricing strategy are critical.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
FTRE • NASDAQ
| Fortrea Holdings Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
REVENUE | ||||||
2.7B | 2.7B | 2.8B | 2.8B | 3.1B | 2.6B | |
GROSS PROFIT | ||||||
(2.3B) | (2.2B) | (2.3B) | (2.1B) | (2.5B) | (2.1B) | |
425.8M | 534.2M | 590.6M | 724.4M | 604.4M | 489.1M | |
OPERATING INCOME | ||||||
(456.4M) | (696.1M) | (558.6M) | (537.3M) | (490.1M) | (803.3M) | |
(456.4M) | (560.7M) | (448.1M) | (416.1M) | (303.1M) | (267.6M) | |
-30.6M | -161.9M | 32M | 187.1M | 114.3M | -314.2M | |
PRE-TAX INCOME | ||||||
(91.4M) | (123.8M) | (69.8M) | (200K) | (200K) | (0.0) | |
-91.4M | -123.8M | -69.7M | -200K | -200K | 0.0 | |
(0.0) | (135.4M) | (110.5M) | (121.2M) | (187M) | (535.7M) | |
-952.4M | -113.1M | -62.5M | -100K | 22.1M | -18M | |
-983M | -275M | -30.5M | 187M | 136.4M | -332.2M | |
NET INCOME | ||||||
(3.2M) | -3.5M | (1.2M) | (41.1M) | (38.4M) | (27M) | |
-986.2M | -328.5M | -25.2M | 186.2M | 98M | -359.2M |
FTRE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 09, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 20, 2025 | November 18, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 22, 2025 | September 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 27, 2025 | August 21, 2025 | 2025 |
Continue your FTRE research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.